Clinical Trial

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the therapeutic efficacy of mosunetuzumab, a bispecific antibody targeting CD20 and CD3 in patients who have detectable chronic lymphocytic leukemia (CLL) after receiving Bruton's tyrosine kinase inhibitors (BTKis) for at least 6 months and have no clinical or laboratory evidence of disease progression.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07566364
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Genentech, Inc.
Conditions Lymphocytic Leukemia
Enrollment 30 participants
Start Date 2026-07-09
Primary Completion 2028-10-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12